Year 2026 / Volume 118 / Number 3
Letter
Combination treatment risankizumab and subcutaneous infliximab for refractory Crohn’s disease

187-188

DOI: 10.17235/reed.2024.10919/2024

Laura Buendía Carcedo, Paz Arreba González, Rebeca Higuera Álvarez, Jone Ortiz de Zárate Sagastagoitia, Carmen Muñoz Villafranca,

Abstract
We present the case of an 18-year-old male who was diagnosed at age 15 with extensive ileal and colonic Crohn's disease with rectal involvement and an associated perianal fistula. The patient received different treatments with biologics without achieving response, thus, combination therapy with subcutaneous Infliximab and Risakizumab was attempted. The patient showed improvement fter the second week, achieving both analytical, clinical and endoscopic response.
New comment
Comments
No comments for this article
References
1- Edward Yang,, Nicola Panaccione, Natalie Whitmire, Parambir S. Dulai, Niels Vande Casteele, Siddharth Singh, Brigid S. Boland, Angelina Collins, William J. Sandborn, , Remo Panaccione, Robert Battat; Efficacy and Safety of Simultaneous Treatment with Two Biologic Medications in Refractory Crohn’s Disease; Aliment Pharmacol Ther. 2020 June ; 51(11): 1031–1038.
2- Goessen et al.: Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases:A European retrospective observational study; United European Gastroenterol J.2021;9:1136–1147
3- Karin Cerna, Martin Kolar, Nadezda Machkova, Veronika Hruba et al; Subcutaneous Infliximab in Refractory Crohn’s Disease Patients: A Possible Biobetter?; Crohn's & Colitis 360, 2023, 5, 1–7 Advance access publication 25 July 2023
4- A. J. Yarur ,V. Kanagala, D. J. Stein, F. Czul, M. A. Quintero, D. Agrawal, A. Patel, K. Best, C. Fox, K. Idstein & M. T. Abreu; Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease; Aliment Pharmacol Ther 2017; 45: 933–940
5- Jean-Frederic Colombel, Silvio Danese, Stefan Schreiber, Bruce ESands,'Andres Yarur, Dong-Hyeon Kim, Young Nam Le, Stephen B, Hanauer D; Impact of immunogenicity on clinical outcomes in patients with Crohn's disease receiving maintenance treatment with subcutaneous infliximab: Apost hoc analysis of the LIBERTY-CD study; P874 European Crohn ´s and Colitis Organisation congress 2024
Related articles

Letter

Perianal Paget’s disease

DOI: 10.17235/reed.2022.9304/2022

Letter to the Editor

Proctitis and perirectal abscesses: is there anything else to think about?

DOI: 10.17235/reed.2018.5500/2018

Citation tools
Buendía Carcedo L, Arreba González P, Higuera Álvarez R, Ortiz de Zárate Sagastagoitia J, Muñoz Villafranca C. Combination treatment risankizumab and subcutaneous infliximab for refractory Crohn’s disease. 10919/2024


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 5 visits.
This article has been downloaded 0 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 05/11/2024

Accepted: 05/12/2024

Online First: 09/01/2025

Published: 06/03/2026

Article Online First time: 65 days

Article editing time: 486 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2026 y Creative Commons. The Spanish Journal of Gastroenterology